Recombinant Erythropoietin Down-Regulates IL-6 and CXCR4 Genes in TNF-α-Treated Primary Cultures of Human Microvascular Endothelial Cells: Implications for Multiple Sclerosis
| Autor: | Seetharama S. Konduru, Jagannadha R. Avasarala |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Receptors
CXCR4 Down-Regulation Blood–brain barrier CXCR4 Cellular and Molecular Neuroscience Gene expression medicine Humans Interleukin 6 Erythropoietin Cells Cultured Oligonucleotide Array Sequence Analysis biology Interleukin-6 Tumor Necrosis Factor-alpha Gene Expression Profiling Multiple sclerosis Endothelial Cells General Medicine medicine.disease Recombinant Proteins Gene expression profiling medicine.anatomical_structure Blood-Brain Barrier Immunology Cancer research biology.protein Tumor necrosis factor alpha medicine.drug |
| Zdroj: | Journal of Molecular Neuroscience. 25:183-190 |
| ISSN: | 0895-8696 |
| DOI: | 10.1385/jmn:25:2:183 |
| Popis: | In multiple sclerosis (MS), disruption of the blood-brain barrier might lead to new gadolinium-enhanced lesion formation in the brain and cause acute relapses. Current therapeutic options for acute relapses in MS are limited. The effect of recombinant erythropoietin (rEPO) on cytokine gene expression in TNF-alpha-treated human brain microvascular endothelial cells was studied. The cells were controls (untreated), exposed for either 6 or 24 h to TNF-alpha or TNF-alpha/rEPO. Of the 96 genes studied, interleukin-6 (IL-6), IL-1beta, CXCR4, and IL-1alpha genes were down-regulated when treated with TNF-alpha/rEPO for 6 h as compared with TNF-alpha alone. At 24 h, IL-6 and CXCR4 gene expression was 4.24 and 2.98, respectively. Quantitative RT-PCR analysis showed down-regulation by 3.86 and 1.9 for IL-6 and CXCR4 genes, respectively. Our findings suggest that further studies are warranted to evaluate the use of EPO in minimizing acute relapses in MS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink